Skip to main content
Premium Trial:

Request an Annual Quote

Mary Taylor New VP Regulatory Affairs at CuraGen; Victor Markowitz to Go From Gene Logic to LBNL; John Keller Appointed to DiaDexus Board; and Others

NEW YORK, Jan.7 (GenomeWeb News) - Mary Taylor has been named as vice president of regulatory affairs at CuraGen, the company said today.


Taylor joins the New Haven, Conn., company following a stint as vice president of North American regulatory affairs at Bayer Pharmaceuticals. Prior to joining Bayer, she was at Parke-Davis Pharmaceutical Research Division of Warner-Lambert, now Pfizer Global Research and Development.



Victor Markowitz told GenomeWeb News Jan. 5 that he is leaving Gene Logic, where he held executive positions for six years, most recently being CIO and senior vice president of data management systems.


Markowitz said he is returning to Lawrence Berkeley National Laboratory to head up a new biological data management and technology center. Prior to joining Gene Logic in 1998, he was a staff scientist and project leader in the Data Management Research and Development group at LBNL.


In November, Gene Logic announced layoffs of 50 staff in database development and production, and said it would add positions in contract study services, marketing, and sales, as part of a shift in its business strategy.



John Keller, executive vice president and chief business officer of Incyte, has been appointed to the board of directors of DiaDexus, the company said Jan. 6.


DiaDexus, a South San Francisco-based company which is privately held, focuses on development and marketing of diagnostic and therapeutic products using genomics and bioinformatics.


Before he took the job at Incyte in September 2003, Keller was vice president of business development at GlaxoSmithKline's worldwide business development group. He was with SmithKline Beecham since 1987.



J. Donald Payne has been appointed to the board of directors of Boston Biomedica, of West Bridgewater, Mass., the company said Jan. 5.


Payne is president and director of Nanospectra Biosciences of Houston, which manufactures medical devices for cancer, opthamology, and diagnostics in the biodefense area. Before joining the company in September 2001, he was senior vice president and CFO of Sensus Drug Development, which was sold to Pharmacia in 2001. He also served as vice president and CFO of LifeCell between 1997 and 1998, and was vice president, finance, and CFO of Aprogenex,a developer and marketer of medical devices that use DNA probes. He also was CFO of private and public entities at UMC Petroleum, and prior to that, worked at Arthur Andersen.



The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.